



Docket No. ORT-1236

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Zhang et al.

Serial No. : 09/603,231

Art Unit: 1655

Filed : June 26, 2000

Examiner: A. Chakrabarti

For : NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR  
ANTAGONISTS

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Assistant Commissioner For Patents, Washington, D.C. 20231 on

November 20, 2001  
(Date of Deposit)

Hal B. Woodrow  
(Name of applicant, assignee, or Registered Representative)

*Hal B. Woodrow*  
(Signature)

November 20, 2001  
(Date of Signature)

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

Applicant(s) reserve(s) the right to establish the  
patentability of the claimed invention over any of the  
information provided herewith, and/or to prove that this  
information may not be prior art, and/or to prove that this

1655  
#46  
RECEIVED  
DEC 12 2001  
TECH CENTER 1000/2000

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached);  
or
- ☐ Please charge Deposit Account No. 10-0750/ /  
the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);  
or  
☒ Please charge Deposit Account No. 10-0750/ORT-  
1236/HBW the fee of \$180.00 as set forth in  
§1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: Nitrogenous heterocyclic derivatives having an  $\alpha_v\beta_3$  integrin inhibitory activity, and being useful for inhibiting neovascularization and preventing post-PTCA restenosis, or salts thereof, and a medicinal composition containing the same.

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1236/HBW. This form is submitted in triplicate.

Respectfully submitted,

Hal B. Woodrow  
Hal B. Woodrow  
Reg. No. 32,501  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2976  
DATED: November 20, 2001